# Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

> **NCT01251978** · PHASE2 · COMPLETED · sponsor: **New England Retina Associates** · enrollment: 10 (actual)

## Conditions studied

- Choroidal Melanoma

## Interventions

- **DRUG:** Ranibizumab 2 mg
- **DRUG:** 0.5 mg Ranibizumab

## Key facts

- **NCT ID:** NCT01251978
- **Lead sponsor:** New England Retina Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251978, "Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01251978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*